| Document |
Document Title |
|
WO/2018/071618A1 |
A microbial indicator device for liquid disinfection comprises a first cavity, a source of biological activity fluidically coupled to the first cavity via a portion of a first fluidic path, a filter membrane positioned in a second fluidi...
|
|
WO/2018/071595A1 |
Provided herein are compounds, methods, and compositions for use in determining the cellular origin of circulating cell-free DNA.
|
|
WO/2018/069343A1 |
The present invention relates to nucleic acids encoding for proteins correlated with the resistance of the Sm1 locus in wheat and uses of these nucleic acids, in particular for conferring or improving resistance to orange wheat blossom m...
|
|
WO/2018/071807A2 |
Provided herein are inhibitor-resistant luciferase mutants, and methods of use thereof. In particular, luciferase mutants are provided that are thermal stable and exhibit improved stability in the presence of luciferin break-down product...
|
|
WO/2018/071296A1 |
Certain embodiments are directed to a self-contained device and the use thereof for amplifying and identifying the presence of a nucleic acid with a specific sequence or sequences.
|
|
WO/2018/071663A1 |
RNA is a prefered composition for delivering genes to target cells for inducing genome editing. While RNA-guided DNA nucleases and their guide-RNA molecules can be easily delivered to a cell as RNA, a donor template is normally delivered...
|
|
WO/2018/071824A1 |
The present invention relates to compositions and methods for predicting response and resistance to CTA4 blockade in melanoma.
|
|
WO/2018/069056A1 |
The invention pertains to a microfluidic cartridge comprising at least one microchannel and at least a set of functionalized microcarriers, the microcarriers being localized within the microchannel, wherein the functionalized microcarrie...
|
|
WO/2018/069355A1 |
Disclosed are methods and devices for fragmenting chains of nucleic acids (such as DNA) in a liquid sample. A liquid sample is provided, comprising chains of nucleic acids. A sample treatment device has a sample treatment zone. The liqui...
|
|
WO/2018/071510A1 |
The present invention relates to the treatment of sarcomas that are driven by oncogenic chimeric transcription factors, such as Ewing Sarcoma and Desmoplastic Small Round Cell Tumor (DSRCT). In some embodiments, the present invention pro...
|
|
WO/2018/069737A1 |
There is provided a method of amplifying a nucleic acid sequence. The method comprises providing an amplification mixture comprising an exonuclease capable of digestion of a strand of a double stranded nucleic acid molecule from the 5'-e...
|
|
WO/2018/070153A1 |
According to the present invention, a dish has a holding recess part provided with: a first portion comprising a tapered part in the vicinity of an opening; a second portion comprising a tubular portion having a vertical inner wall surfa...
|
|
WO/2018/071295A1 |
Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked...
|
|
WO/2018/071493A1 |
A novel receptor for GDF15 was identified (GFRAL), as well as the use of this receptor in the identification or screening of GDF15 agonists or antagonists. These agonist or antagonist compounds may be used to either potentiate or suppres...
|
|
WO/2018/071362A1 |
Compositions and methods for obtaining plant cells with modified Ht1 nucleotide sequences, modified NLB18 sequences, or both, are provided herein. The methods involve introducing double-strand breaks into the maize genome in an endogenou...
|
|
WO/2018/069470A1 |
The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new...
|
|
WO/2018/069866A1 |
Certain embodiments of the invention are directed to evaluating and identifying cells by recording and interpreting a time-dependent signal produced by unique cell respiration and permeability attributes of isolated viable cells.
|
|
WO/2018/070652A1 |
The present invention relates to a kit for hemoglobin A1c quantitative analysis, and according to the present invention, the kit for hemoglobin A1c quantitative analysis has excellent long-term stability of enzyme reagents, thereby havin...
|
|
WO/2018/069267A1 |
The disclosure provides control compositions used in nucleic acid amplification. Various modifications to the disclosed compositions and methods of using the same, devices, and kits are described.
|
|
WO/2018/071154A1 |
The present invention provides an invasive cancer stem cell (iCSC) or a substantively homogeneous cell population including said iCSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iCSC. The present ...
|
|
WO/2018/070659A1 |
Disclosed in the present application is a method capable of specifically detecting a polymorphism in a target nucleic acid through isothermal amplification. According to the present application, the method can rapidly detect, with high s...
|
|
WO/2018/071541A1 |
An integrated molecular diagnostics system (iMDx) for the detection of Dengue Fever at point-of-care, wherein blood plasma separation for the selective separation of the Dengue virus from the whole blood, LED-driven photothermal lysis of...
|
|
WO/2018/069430A1 |
A method for identifying a pathogen contained in a metagenomic sample and for identifying pathogenic markers in the genome of said pathogen comprises: - processing (12) the sample to extract DNA from pathogens, - sequencing (14) the extr...
|
|
WO/2018/071522A1 |
In some embodiments, the disclosure relates generally to methods, and related compositions, systems, kits and apparatuses, for conducting a stream-lined nucleic acid library preparation workflow that generally includes binding a polynucl...
|
|
WO/2018/069885A1 |
Provided are methods of selecting a treatment for a cancer in a subject in need thereof, by analyzing activity of Yes associated protein 1 (YAP) in cancer cells of the subject, and methods of treating cancer using a therapeutically effec...
|
|
WO/2018/071502A1 |
Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diag...
|
|
WO/2018/071524A1 |
The present invention provides compositions and methods for identifying likelihood of relapse/remission in a subject having ANCA-associated vasculitis (AAV).
|
|
WO/2018/069612A1 |
The present invention relates to a device and to a method for preparing a sample likely to contain at least one target microorganism, said method comprising the following steps: a) placing said sample in a container (1) comprising: - a d...
|
|
WO/2018/069450A1 |
A method is provided for determining non-small cell lung cancer, a predisposition to non-small cell lung cancer, or the prognosis of a non-small cell lung cancer in a subject, said method comprising in a sample from said subject determin...
|
|
WO/2018/069494A1 |
The invention relates to a method to predict a patient's risk of developing prostate cancer, or to distinguish indolent vs. aggressive cancers among patients suspected of bearing PCa and therefore selected for biopsy, and/or predict the ...
|
|
WO/2018/071841A1 |
The present invention features modified polynucleotide sequences that mimic host cell DNA and methods of using such sequences for the genetic engineering of bacteria that are otherwise genetically intractable.
|
|
WO/2018/071519A1 |
Methods for diagnosing, treating, and monitoring the treatment of fusariosis or scedosporiosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspe...
|
|
WO/2018/069538A1 |
The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (...
|
|
WO/2018/071672A1 |
Disclosed herein are engineered nucleases and nuclease systems, including chimeric nucleases and chimeric nuclease systems. Engineered and chimeric nucleases disclosed herein include nucleic acid guided nucleases. Additionally disclosed ...
|
|
WO/2018/071354A1 |
Described herein are apparatus, including multi-tissue body-on-a-chip apparatus. In some embodiments, described are apparatus including at least a first, second, and third chamber in fluid communication with one another and with at least...
|
|
WO/2018/071556A1 |
Provided are methods of identifying, visualizing and purifying proteases from a complex biological sample.
|
|
WO/2018/071732A1 |
A system for testing the efficacy of a sterilization process includes a bioindicator housing a genetically modified test microorganism modified with a heterologous reporter gene, and a detection apparatus for detecting the presence or ab...
|
|
WO/2018/070346A1 |
The present invention provides a novel tissue that can be used as a kidney tissue model. A production method for kidney-like tissue, the production method involving coculturing a cell group that includes mesenchymal stem cells, vascular ...
|
|
WO/2018/071440A1 |
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women, and in particular embodiments, methods for treating ER+ cancers having gain of function mutations in the ESR1 ligand binding domain, with an e...
|
|
WO/2018/071273A1 |
The invention is directed to optically based methods for nanopore sequencing of polynucleotides which comprise steps of (i) translocating a polynucleotide through a bore of a nanopore at a translocation speed, wherein nucleotides of the ...
|
|
WO/2018/069484A2 |
Provided herein are methods and compositions for detecting and/or quantitating target analytes, including nucleic acids and polypeptides, using nanopore detectable barcodes.
|
|
WO/2018/070524A1 |
Provided are: a screening method suited for screening for a blood IgA production inhibitor, a blood IgA production accelerating agent, or a prophylactic or therapeutic agent against diseases caused by excessive IgA in the blood; a blood ...
|
|
WO/2018/069232A1 |
Inventors have measured plasma iFGF23 and C-terminal FGF23 (cFGF23) concentrations in 77 young adult SCD patients and in 172 healthy control subjects. Plasma cFGF23 but not iFGF23 concentration was higher in SCD patients than in control ...
|
|
WO/2018/067792A1 |
The present invention generally relates to sequencing of cells such as bacteria or archeons. In one aspect, cells are lysed to release RNA, which is then polyadenylated and exposed to a sequencing having an identification portion and a p...
|
|
WO/2018/067330A1 |
Embodiments of the disclosure concern methods and compositions that include a substrate that comprises at least one fluorophore in sufficient amounts and delivery of the substrate to an individual in need of treatment. In specific embodi...
|
|
WO/2018/065656A1 |
The present invention relates to a sensor (1) for measuring pH and the concentration of different analytes in a sweat sample from an individual. More specifically, the sensor (1) can be worn by an individual to carry out measurements con...
|
|
WO/2018/066701A1 |
Provided is a prophylactic or therapeutic agent for frontotemporal lobar degeneration (FTLD), said agent comprising an inhibitor of calcium ion influx into cells. Also provided is a method for screening a prophylactic or therapeutic agen...
|
|
WO/2018/065101A1 |
A method and an analysis system for testing an in particular biological sample are proposed, nucleic-acid products being hybridised to capture molecules of a sensor apparatus at different temperatures.
|
|
WO/2018/067937A1 |
A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative a...
|
|
WO/2018/067449A1 |
A method for assaying endoglycosidase activity includes providing a proteoglycan having a glycosaminoglycan chain with a non-reducing end; treating the proteoglycan with a glycosyltransferase to incorporate a carbohydrate into the non-re...
|
